Rituximab for Secondary Progressive Multiple Sclerosis: A Case Series

Authors: Rommer, Paulus S.; Patejdl, Robert; Winkelmann, Alexander; Benecke, Reiner; Zettl, Uwe K.

Source: CNS Drugs, Volume 25, Number 7, 1 July 2011 , pp. 607-613(7)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

Background While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS).

Objectives and Methods In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months.

Results During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis.

Conclusion Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis.

Keywords: Monoclonal-antibodies; Multiple-sclerosis; Rituximab

Document Type: Short communication

Affiliations: 1: 1 Department of Neurology, University of Rostock, Rostock, Germany

Publication date: 2011-07-01